Affiliations 

  • 1 School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada. Electronic address: sehorton@uwaterloo.ca
  • 2 Institute of Cancer Policy, King's College, London, UK
  • 3 Center for Global Health, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
  • 4 Center for Global Health, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Green Templeton College, University of Oxford, Oxford, UK
  • 5 Department of Chemical Pathology, College of Medicine, University of Ibadan, and University Hospital, Ibadan, Nigeria
  • 6 Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 7 Columbia Asia Referral Hospital, Bangalore, India
  • 8 Faculty of Medicine, Health and Life Sciences and Centre for Cancer Research and Cell Biology, Queens University, Belfast, UK
Lancet, 2018 05 12;391(10133):1953-1964.
PMID: 29550030 DOI: 10.1016/S0140-6736(18)30460-4

Abstract

Modern, affordable pathology and laboratory medicine (PALM) systems are essential to achieve the 2030 Sustainable Development Goals for health in low-income and middle-income countries (LMICs). In this last in a Series of three papers about PALM in LMICs, we discuss the policy environment and emphasise three crucial high-level actions that are needed to deliver universal health coverage. First, nations need national strategic laboratory plans; second, these plans require adequate financing for implementation; and last, pathologists themselves need to take on leadership roles to advocate for the centrality of PALM to achieve the Sustainable Development Goals for health. The national strategic laboratory plan should deliver a tiered, networked laboratory system as a central element. Appropriate financing should be provided, at a level of at least 4% of health expenditure. Financing of new technologies such as molecular diagnostics is challenging for LMICs, even though many of these tests are cost-effective. Point-of-care testing can substantially reduce test-reporting time, but this benefit must be balanced with higher costs. Our research analysis highlights a considerable deficiency in advocacy for PALM; pathologists have been invisible in national and international health discourse and leadership. Embedding PALM in LMICs can only be achieved if pathologists advocate for these services, and undertake leadership roles, both nationally and internationally. We articulate eight key recommendations to address the current barriers identified in this Series and issue a call to action for all stakeholders to come together in a global alliance to ensure the effective provision of PALM services in resource-limited settings.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.